The global market for epigenetics research tools and reagents, IVDs and therapeutics is expected to grow from $4.8 billion in 2024 to $8.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.8% from 2024 through 2029.
Epigenetics is the study of heritable changes in gene expression or activity that do not involve alterations to the DNA sequence itself. The global market for epigenetics research tools and reagents by study method was estimated at $1.8 billion in 2023. This market should reach $2.2 billion by the end of 2029, growing at a CAGR of 4.1% through the forecast period. The demand for new research tools remains constant as scientists strive to advance understanding and pursue groundbreaking discoveries.
The mounting clinical evidence supporting the relevance of epigenetics in various diseases has fueled a surge in epigenetic research, thereby increasing the demand for high-quality reagents and research tools. The trend is expected to continue over the forecast period, yielding market growth.
Epigenetic therapeutics target and modulate epigenetic mechanisms to restore a more normal epigenomic configuration. The global market for epigenetic therapeutics market by drug class targeting DNMT, IDH, HDAC and EZH2 was estimated at $938.2 million in 2023. The market is expected to reach $1.9 billion by the end of 2029, growing at a CAGR of 11% over the forecast period. Emerging research demonstrates the potential of epigenetics-based therapeutics as a versatile and targeted treatment modality, offering a viable alternative to conventional chemotherapy. Scientific advances, the growing number of cancer patients and the unmet need in oncology are key growth factors of the epigenetic drugs market.
In this report, the analyst estimated market data for 2023 (base year) and forecasts values for 2024 through 2029. The research tools and reagents market segmentation is based on the study methods. Epigenetic biomarker-based IVDs market segmentation is based on clinical indications. Epigenetics targeted therapeutics market segmentation is based on drug class. This report also provides regional analyses for epigenetics products.
This report analyzes industry growth drivers, restraints, trends and opportunities in the epigenetics market. The report also covers the competitive landscape and latest trends in epigenetics products. Emerging technologies that impact the epigenetics market are also discussed, along with current information about new products, acquisitions and collaborations related to the epigenetics market.
Epigenetics is the study of heritable changes in gene expression or activity that do not involve alterations to the DNA sequence itself. The global market for epigenetics research tools and reagents by study method was estimated at $1.8 billion in 2023. This market should reach $2.2 billion by the end of 2029, growing at a CAGR of 4.1% through the forecast period. The demand for new research tools remains constant as scientists strive to advance understanding and pursue groundbreaking discoveries.
The mounting clinical evidence supporting the relevance of epigenetics in various diseases has fueled a surge in epigenetic research, thereby increasing the demand for high-quality reagents and research tools. The trend is expected to continue over the forecast period, yielding market growth.
Epigenetic therapeutics target and modulate epigenetic mechanisms to restore a more normal epigenomic configuration. The global market for epigenetic therapeutics market by drug class targeting DNMT, IDH, HDAC and EZH2 was estimated at $938.2 million in 2023. The market is expected to reach $1.9 billion by the end of 2029, growing at a CAGR of 11% over the forecast period. Emerging research demonstrates the potential of epigenetics-based therapeutics as a versatile and targeted treatment modality, offering a viable alternative to conventional chemotherapy. Scientific advances, the growing number of cancer patients and the unmet need in oncology are key growth factors of the epigenetic drugs market.
Report Scope
This report comprehensively analyzes the global market for epigenetics products, research tools and reagents, epigenetic biomarker-based in vitro diagnostics (IVDs) and epigenetics-targeted therapeutics. It offers both quantitative and qualitative insights to help readers formulate growth strategies, evaluate the market landscape, assess their competitive positions and make informed business decisions regarding epigenetics products and services. The scope of epigenetics-targeted therapeutics includes DNA methyltransferase (DNMT) inhibitors, histone deacetylase (HDAC) inhibitors, isocitrate dehydrogenase (IDH) inhibitors and zeste homolog 2 (EZH2) inhibitors.In this report, the analyst estimated market data for 2023 (base year) and forecasts values for 2024 through 2029. The research tools and reagents market segmentation is based on the study methods. Epigenetic biomarker-based IVDs market segmentation is based on clinical indications. Epigenetics targeted therapeutics market segmentation is based on drug class. This report also provides regional analyses for epigenetics products.
This report analyzes industry growth drivers, restraints, trends and opportunities in the epigenetics market. The report also covers the competitive landscape and latest trends in epigenetics products. Emerging technologies that impact the epigenetics market are also discussed, along with current information about new products, acquisitions and collaborations related to the epigenetics market.
The report includes:
- 25 data tables and 66 additional tables
- Analyses of the trends in global markets for epigenetics technologies, with market revenue data from 2021 to 2023, estimates for 2024, and projected CAGRs through 2029
- Estimates of the size and growth forecasts of the global epigenomics market, and a corresponding market share analysis by product type, study method, clinical indication, drug class and region
- Facts and figures pertaining to the market dynamics, technological advancements, regulatory landscape, and the impact of macroeconomic factors
- Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses
- Evaluation of recent patent activity and key granted and published patents in the industry
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
- Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
- Profiles of leading companies, including Bristol-Myers Squibb Co., Les Laboratoires Servier, Exact Sciences Corp., Thermo Fisher Scientific Inc., and Qiagen
Table of Contents
Chapter 1 Executive Summary
Chapter 2 Market Overview
Chapter 3 Market Dynamics
Chapter 4 Emerging Technologies and Developments
Chapter 5 Market Segmentation Analysis
Chapter 6 Competitive Intelligence
Chapter 7 Sustainability in the Epigenetics Market: An ESG Perspective
Chapter 8 Appendix
List of Tables
List of Figures
Companies Mentioned
- Active Motif Inc.
- Bio-Rad Laboratories Inc.
- Bio-Techne
- Bristol-Myers Squibb Co.
- Daiichi Sankyo Co. Ltd.
- Exact Sciences Corp.
- Guardant Health
- Hologic Inc.
- Les Laboratoires Servier
- Merck KGaA
- Nucleix
- Promega Corp.
- Qiagen
- Revvity Inc. (Perkinelmer)
- Thermo Fisher Scientific Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 115 |
| Published | March 2025 |
| Forecast Period | 2024 - 2029 |
| Estimated Market Value ( USD | $ 4.8 Billion |
| Forecasted Market Value ( USD | $ 8.5 Billion |
| Compound Annual Growth Rate | 11.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
